鼻咽癌相关分子标志物的研究进展
|
摘要
鼻咽癌是我国南方常见的恶性肿瘤,其发生涉及多个阶段过程。虽然近年来鼻咽癌的诊断和治疗水平有明显提高,但鼻咽癌的死亡率仍然很高。随着现代分子生物学的发展,许多新的分子标志物的出现给鼻咽癌的预防、诊断、治疗和预后等各个方面带来了新的希望。全文就近年来一些鼻咽癌各阶段相关分子标志物的研究进展做一综述。
Nasopharyngeal carcinoma(NPC) is a common malignant tumor in southern China. Although the diagnosis and treatment of nasopharyngeal carcinoma have been greatly improved in recent years,the mortality of nasopharyngeal carcinoma is still high. With the development of molecular biology,many new molecular markers have been discovered,bringing new hope to the prevention,diagnosis,treatment and prognosis of nasopharyngeal carcinoma. This article reviews the research progress on the molecular markers related to nasopharyngeal carcinoma.
Nasopharyngeal carcinoma(NPC) is a common malignant tumor in southern China. Although the diagnosis and treatment of nasopharyngeal carcinoma have been greatly improved in recent years,the mortality of nasopharyngeal carcinoma is still high. With the development of molecular biology,many new molecular markers have been discovered,bringing new hope to the prevention,diagnosis,treatment and prognosis of nasopharyngeal carcinoma. This article reviews the research progress on the molecular markers related to nasopharyngeal carcinoma.
引文
[1] Zhang WL,Zhou YH,Xiao L,et al. Biomarkers of nasopharyngeal carcinoma[J]. Progress in Biochemistry and Biophysics,2008,35(1):7-13.[张文玲,周艳宏,肖岚,等.鼻咽癌分子标志物研究[J].生物化学与生物物理进展,2008,35(1):7-13.]
[2] Li J,Zhou C,Wang G,et al. Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma[J]. Gene,2018,644:74-79.
[3] Ye M,Huang T,Ni C,et al. Diagnostic capacity of RASSF1A promoter methylation as a biomarker in tissue,brushing,and blood samples of nasopharyngeal carcinoma[J]. EBioMedicine,2017,18:32-40.
[4] Peng YH,Xu YW,Huang LS,et al. Autoantibody signatures combined with Epstein-Barr virus capsid antigen-IgA as a biomarker panel for the detection of nasopharyngeal carcinoma[J]. Cancer Pre Res,2015,8(8):729-736.
[5] Shi X,Chen X,Li WC et al. Low expression of Cyfip1may be a potential biomarker in nasopharyngeal carcinoma[J].Neoplasma,2018,65(2):292-295.
[6] Luo Y,Mok TS,Lin X,et al. SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma[J]. Sci Rep,2017,7:41191.
[7] Jia W,Ren C,Wang L,et al. CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX[J]. Oncotarget,2016,7(34):55328-55342.
[8] Khor LK,Loi HY,Sinha AK,et al.(68)Ga-DOTA-peptide:a novel molecular biomarker for nasopharyngeal carcinoma[J]. Head Neck,2016,38(4):E76-E80.
[9] Wang Z,Luo F,Li L,et al. STAT3 activation induced by Epstein-Barr virus latent membrane protein 1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 and ERK signaling[J]. Eur J Cancer,2011,46(16):2996-3006.
[10] Horikawa T,Yang J,Kondo S,et al. Twist and epithelial mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma[J]. Cancer Res,2007,67(5):1970-1978.
[11] Wen Q,Li J,Wang W,et al. Increased expression of flotillin-2 protein as a novel biomarker for lymph node metastasis in nasopharyngeal carcinoma[J]. PLoS One,2014,9(7):e101676.
[12] Lu J,Xu X,Liu X,et al. Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis[J]. Br J Cancer,2014,110(2):392-398.
[13] Li XH,Chang H,Xu BQ,et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma:an analysis of a prospective study[J]. Cancer Med,2017,6(1):310-319.
[14] Chen J,Li S,Xiao Y,et al. p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma.[J]. BMC Cancer,2017,17(1):846.
[15] Ye SB,Zhang H,Cai TT,et al. Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma[J]. J Pathol,2016,240(3):329-340.
[16] Chen Q,Qin S,Liu Y,et al. IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker[J]. Oncotarget,2016,7(42):68140-68150.
[17] Zhao FP,Liu X,Zhong ZM,et al. Positivity of both plasma Epstein-Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma[J]. BBA Clin,2014,2:88-93.
[18] Liu ZH,Hu JL,Liang JZ,et al. Far upstream elementbinding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression[J]. Cell Death Dis,2015,6:e1920.
[19] Deng CC,Xu M,Li J,et al. Unconjugated bilirubin is a novel prognostic biomarker for nasopharyngeal carcinoma and inhibits its metastasis via antioxidation activity[J].Cancer Pre Res,2016,9(2):180-188.
[20] Zeng GQ,Cheng AL,Tang J,et al. Annexin A1:a new biomarker for predicting nasopharyngeal carcinoma response to radiotherapy[J]. Med Hypotheses,2013,81(1):68-70.
[21] Cai MY,Tong ZT,Zhu W,et al. H3K27me3 protein is a promising predictive biomarker of patients’ survival and chemoradioresistance in human nasopharyngeal carcinoma[J]. Mol Med,2011,17(11-12):1137-1145.
[22] Ping WU,Hua Z,Lin QI,et al. Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy[J]. Oncol Rep,2012,27(4):987-994.
[23] Sun QQ,Liu X,Liu Y,et al. Effect of shRNAmir lentiviral vector-mediated COX-2 silencing on the radiosensitivity of nasopharyngeal carcinoma cells[J]. Nan Fang Yi Ke Da Xue Xue Bao,2011,31(4):599-603.
[24] Scorilas A,Kyriakopoulou L,Yousef GM,et al. Molecular cloning,physical mapping,and expression analysis of a novel gene,BCL2L12,encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family[J].Genomics,2001,72(2):217-221.
[25] Fendri A,Kontos CK,Khabir A,et al. BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma[J]. Mol Med,2011,17(3-4):163-171.
[26] Wan XB,Wei L,Li H,et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma[J]. Eur J Cancer,2013,49(10):2356-2364.
[2] Li J,Zhou C,Wang G,et al. Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma[J]. Gene,2018,644:74-79.
[3] Ye M,Huang T,Ni C,et al. Diagnostic capacity of RASSF1A promoter methylation as a biomarker in tissue,brushing,and blood samples of nasopharyngeal carcinoma[J]. EBioMedicine,2017,18:32-40.
[4] Peng YH,Xu YW,Huang LS,et al. Autoantibody signatures combined with Epstein-Barr virus capsid antigen-IgA as a biomarker panel for the detection of nasopharyngeal carcinoma[J]. Cancer Pre Res,2015,8(8):729-736.
[5] Shi X,Chen X,Li WC et al. Low expression of Cyfip1may be a potential biomarker in nasopharyngeal carcinoma[J].Neoplasma,2018,65(2):292-295.
[6] Luo Y,Mok TS,Lin X,et al. SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma[J]. Sci Rep,2017,7:41191.
[7] Jia W,Ren C,Wang L,et al. CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX[J]. Oncotarget,2016,7(34):55328-55342.
[8] Khor LK,Loi HY,Sinha AK,et al.(68)Ga-DOTA-peptide:a novel molecular biomarker for nasopharyngeal carcinoma[J]. Head Neck,2016,38(4):E76-E80.
[9] Wang Z,Luo F,Li L,et al. STAT3 activation induced by Epstein-Barr virus latent membrane protein 1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 and ERK signaling[J]. Eur J Cancer,2011,46(16):2996-3006.
[10] Horikawa T,Yang J,Kondo S,et al. Twist and epithelial mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma[J]. Cancer Res,2007,67(5):1970-1978.
[11] Wen Q,Li J,Wang W,et al. Increased expression of flotillin-2 protein as a novel biomarker for lymph node metastasis in nasopharyngeal carcinoma[J]. PLoS One,2014,9(7):e101676.
[12] Lu J,Xu X,Liu X,et al. Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis[J]. Br J Cancer,2014,110(2):392-398.
[13] Li XH,Chang H,Xu BQ,et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma:an analysis of a prospective study[J]. Cancer Med,2017,6(1):310-319.
[14] Chen J,Li S,Xiao Y,et al. p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma.[J]. BMC Cancer,2017,17(1):846.
[15] Ye SB,Zhang H,Cai TT,et al. Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma[J]. J Pathol,2016,240(3):329-340.
[16] Chen Q,Qin S,Liu Y,et al. IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker[J]. Oncotarget,2016,7(42):68140-68150.
[17] Zhao FP,Liu X,Zhong ZM,et al. Positivity of both plasma Epstein-Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma[J]. BBA Clin,2014,2:88-93.
[18] Liu ZH,Hu JL,Liang JZ,et al. Far upstream elementbinding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression[J]. Cell Death Dis,2015,6:e1920.
[19] Deng CC,Xu M,Li J,et al. Unconjugated bilirubin is a novel prognostic biomarker for nasopharyngeal carcinoma and inhibits its metastasis via antioxidation activity[J].Cancer Pre Res,2016,9(2):180-188.
[20] Zeng GQ,Cheng AL,Tang J,et al. Annexin A1:a new biomarker for predicting nasopharyngeal carcinoma response to radiotherapy[J]. Med Hypotheses,2013,81(1):68-70.
[21] Cai MY,Tong ZT,Zhu W,et al. H3K27me3 protein is a promising predictive biomarker of patients’ survival and chemoradioresistance in human nasopharyngeal carcinoma[J]. Mol Med,2011,17(11-12):1137-1145.
[22] Ping WU,Hua Z,Lin QI,et al. Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy[J]. Oncol Rep,2012,27(4):987-994.
[23] Sun QQ,Liu X,Liu Y,et al. Effect of shRNAmir lentiviral vector-mediated COX-2 silencing on the radiosensitivity of nasopharyngeal carcinoma cells[J]. Nan Fang Yi Ke Da Xue Xue Bao,2011,31(4):599-603.
[24] Scorilas A,Kyriakopoulou L,Yousef GM,et al. Molecular cloning,physical mapping,and expression analysis of a novel gene,BCL2L12,encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family[J].Genomics,2001,72(2):217-221.
[25] Fendri A,Kontos CK,Khabir A,et al. BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma[J]. Mol Med,2011,17(3-4):163-171.
[26] Wan XB,Wei L,Li H,et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma[J]. Eur J Cancer,2013,49(10):2356-2364.